Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03685578 · ClinicalTrials.gov registry record
CERENOVUS Neurothrombectomy Devices Registry
A clinical trial, sponsored by Cerenovus, Part of DePuy Synthes Products.
- Completed
- Registry status
- 2,000
- Enrollment target
NCT03685578: Completed study, sponsored by Cerenovus, Part of DePuy Synthes Products.
NCT03685578 is a clinical trial that has completed, run by Cerenovus, Part of DePuy Synthes Products. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03685578 has completed, sponsored by Cerenovus, Part of DePuy Synthes Products.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.
Primary Outcome
Assess cerebral revascularization using the modified Thrombolysis in Cerebral Infarction (mTICI) score at the end of the procedure.
Interventions
- DEVICE EmboTrap® Revascularization Device
- DEVICE CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
- DEVICE CEREGLIDE 71 Intermediate Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2025-02-20 |
What the finished NCT03685578 record still lists
NCT03685578 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which EmboTrap® Revascularization Device is the first listed.
NCT03685578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03685578 about?
NCT03685578 is a clinical study titled "CERENOVUS Neurothrombectomy Devices Registry". A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.
What is the current status of trial NCT03685578?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2018-09-28. Estimated completion is 2025-02-20.
What interventions are being tested in trial NCT03685578?
The interventions under investigation include: EmboTrap® Revascularization Device (DEVICE), CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter (DEVICE), CEREGLIDE 71 Intermediate Catheter (DEVICE).
Who is sponsoring clinical trial NCT03685578?
This trial is sponsored by Cerenovus, Part of DePuy Synthes Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI